Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 13,378 | $3.22 | $43.08kBuy |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 3,345 | $2.92 | $9.77kBuy |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 8,378 | $25.11 | $210.39kSell |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 5,000 | $25.11 | $125.56kSell |
Karen Akinsanya | President of RD Therapeutics | 2025-04-14 | 3,345 | $25.00 | $83.63kSell |
Jenny Herman | SVP Controller | 2025-03-06 | 666 | $21.11 | $14.06kSell |
Geoffrey Craig Porges | EVP CFO | 2025-03-03 | 5,491 | $21.76 | $119.48kSell |
Yvonne Tran | EVP CLO CPO | 2025-02-18 | 3,902 | $28.00 | $109.26kSell |
Yvonne Tran | EVP CLO CPO | 2025-02-18 | 3,902 | $4.34 | $16.93kBuy |
Jenny Herman | SVP Controller | 2025-02-11 | 859 | $24.43 | $20.99kSell |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Blackrock Inc | 11.53% | 8,463,746 | $181.29M | Institution |
Melinda Gates Foundation Trust Bill | 9.51% | 6,981,664 | $149.55M | Insider |
Gates Foundation Trust | 9.51% | 6,981,664 | $149.55M | Institution |
Vanguard Group Inc | 8.92% | 6,543,845 | $140.17M | Institution |
David E. Shaw | 8.44% | 6,196,609 | $132.73M | Insider |
Rubric Capital Management LP | 6.54% | 4,800,000 | $102.82M | Institution |
Ubs Am A Distinct Business Unit Of Ubs Asset Management Americas LLC | 5.94% | 4,357,532 | $93.34M | Institution |
Sumitomo Mitsui Trust Group Inc | 4.72% | 3,462,415 | $74.16M | Institution |
Nikko Asset Management Americas Inc | 3.29% | 2,416,808 | $51.77M | Institution |
Ark Investment Management LLC | 3.13% | 2,294,519 | $49.15M | Institution |